Twist Bioscience Corporation Comprehensive Income
Twist Bioscience Corporation (TWST) reported Comprehensive Income of -$35.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-03
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$35.07M, a 273.70% decline year-over-year.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$44.09M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$30.45M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$26.90M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$77.78M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$208.49M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$203.53M.
- Twist Bioscience Corporation comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$220.25M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$35.07M 10-Q · filed 2026-08-03 | -$79.16M derived: sum of 2 quarters · filed 2026-08-03 | -$109.61M 10-Q · filed 2026-08-03 | -$136.51M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$44.09M 10-Q · filed 2026-05-04 | -$74.54M 10-Q · filed 2026-05-04 | -$101.44M derived: sum of 3 quarters · filed 2026-05-04 | -$81.25M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$30.45M 10-Q/A · filed 2026-02-26 | -$57.35M derived: sum of 2 quarters · filed 2026-02-26 | -$37.16M derived: sum of 3 quarters · filed 2026-08-03 | -$76.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-09-30 | -$26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$6.71M derived: sum of 2 quarters · filed 2026-08-03 | -$46.04M derived: sum of 3 quarters · filed 2026-08-03 | -$77.78M 10-K · filed 2025-11-17 |
| 2025-06-30 | $20.19M 10-Q · filed 2026-08-03 | -$19.14M derived: sum of 2 quarters · filed 2026-08-03 | -$50.87M 10-Q · filed 2026-08-03 | -$85.30M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$39.32M 10-Q · filed 2026-05-04 | -$70.78M 10-Q · filed 2026-05-04 | -$105.49M derived: sum of 3 quarters · filed 2026-05-04 | -$191.13M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$31.72M 10-Q/A · filed 2026-02-26 | -$66.16M derived: sum of 2 quarters · filed 2026-02-26 | -$151.81M derived: sum of 3 quarters · filed 2026-02-26 | -$197.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-09-30 | -$34.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$120.09M derived: sum of 2 quarters · filed 2025-11-17 | -$165.68M derived: sum of 3 quarters · filed 2025-11-17 | -$208.49M 10-K · filed 2025-11-17 |
| 2024-06-30 | -$85.65M 10-Q · filed 2025-08-04 | -$131.23M derived: sum of 2 quarters · filed 2025-08-04 | -$174.05M 10-Q · filed 2025-08-04 | -$220.41M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-03-31 | -$45.59M 10-Q · filed 2025-05-05 | -$88.40M 10-Q · filed 2025-05-05 | -$134.77M derived: sum of 3 quarters · filed 2025-11-17 | -$192.91M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-12-31 | -$42.82M 10-Q · filed 2025-02-03 | -$89.18M derived: sum of 2 quarters · filed 2025-11-17 | -$147.32M derived: sum of 3 quarters · filed 2025-11-17 | -$205.76M derived: sum of 4 quarters · filed 2025-11-17 |
| 2023-09-30 | -$46.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | -$104.50M derived: sum of 2 quarters · filed 2025-11-17 | -$162.94M derived: sum of 3 quarters · filed 2025-11-17 | -$203.53M 10-K · filed 2025-11-17 |
| 2023-06-30 | -$58.14M 10-Q · filed 2024-08-02 | -$116.58M derived: sum of 2 quarters · filed 2024-08-02 | -$157.17M 10-Q · filed 2024-08-02 | -$211.22M derived: sum of 4 quarters · filed 2024-11-18 |
| 2023-03-31 | -$58.44M 10-Q · filed 2024-05-02 | -$99.03M 10-Q · filed 2024-05-02 | -$153.07M derived: sum of 3 quarters · filed 2024-11-18 | -$214.49M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-12-31 | -$43.06M 10-Q · filed 2024-02-02 | -$94.64M derived: sum of 2 quarters · filed 2024-11-18 | -$156.06M derived: sum of 3 quarters · filed 2024-11-18 | -$217.56M derived: sum of 4 quarters · filed 2024-11-18 |
| 2022-09-30 | -$51.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | -$113.00M derived: sum of 2 quarters · filed 2024-11-18 | -$174.51M derived: sum of 3 quarters · filed 2024-11-18 | -$220.25M 10-K · filed 2024-11-18 |
| 2022-06-30 | -$61.42M 10-Q · filed 2023-08-07 | -$122.92M derived: sum of 2 quarters · filed 2023-08-07 | -$168.67M 10-Q · filed 2023-08-07 | -$209.43M derived: sum of 4 quarters · filed 2023-11-21 |
| 2022-03-31 | -$61.51M 10-Q · filed 2023-05-08 | -$107.25M 10-Q · filed 2023-05-08 | -$148.01M derived: sum of 3 quarters · filed 2023-11-21 | -$187.81M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-12-31 | -$45.38M 10-Q · filed 2023-02-07 | -$86.50M derived: sum of 2 quarters · filed 2023-11-21 | -$126.30M derived: sum of 3 quarters · filed 2023-11-21 | -$164.17M derived: sum of 4 quarters · filed 2023-11-21 |
| 2021-09-30 | -$41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | -$80.92M derived: sum of 2 quarters · filed 2023-11-21 | -$118.79M derived: sum of 3 quarters · filed 2023-11-21 | -$151.64M 10-K · filed 2023-11-21 |
| 2021-06-30 | -$39.80M 10-Q · filed 2022-08-08 | -$77.67M derived: sum of 2 quarters · filed 2022-08-08 | -$110.52M 10-Q · filed 2022-08-08 | -$134.88M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | -$37.87M 10-Q · filed 2022-05-06 | -$70.72M 10-Q · filed 2022-05-06 | -$95.08M derived: sum of 3 quarters · filed 2023-06-05 | -$123.37M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | -$32.84M 10-Q · filed 2022-02-09 | -$57.21M derived: sum of 2 quarters · filed 2023-06-05 | -$85.50M derived: sum of 3 quarters · filed 2023-06-05 | -$117.24M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | -$24.36M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | -$52.65M derived: sum of 2 quarters · filed 2023-06-05 | -$84.40M derived: sum of 3 quarters · filed 2023-06-05 | -$140.03M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | -$28.29M 10-Q · filed 2021-08-09 | -$60.03M derived: sum of 2 quarters · filed 2021-08-09 | -$115.66M 10-Q · filed 2021-08-09 | -$146.78M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | -$31.75M 10-Q · filed 2021-05-07 | -$87.37M 10-Q · filed 2021-05-07 | -$118.49M derived: sum of 3 quarters · filed 2021-11-23 | -$146.15M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | -$55.63M 10-Q · filed 2021-02-09 | -$86.75M derived: sum of 2 quarters · filed 2021-11-23 | -$114.41M derived: sum of 3 quarters · filed 2021-11-23 | -$140.50M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-09-30 | -$31.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | -$58.78M derived: sum of 2 quarters · filed 2021-11-23 | -$84.87M derived: sum of 3 quarters · filed 2021-11-23 | -$107.58M 10-K · filed 2021-11-23 |
| 2019-06-30 | -$27.66M 10-Q · filed 2020-08-12 | -$53.76M derived: sum of 2 quarters · filed 2020-08-12 | -$76.46M 10-Q · filed 2020-08-12 | -$96.24M derived: sum of 4 quarters · filed 2020-11-27 |
| 2019-03-31 | -$26.09M 10-Q · filed 2020-05-13 | -$48.80M 10-Q · filed 2020-05-13 | -$68.58M derived: sum of 3 quarters · filed 2020-11-27 | -$86.19M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-12-31 | -$22.70M 10-Q · filed 2020-02-10 | -$42.48M derived: sum of 2 quarters · filed 2020-11-27 | -$60.09M derived: sum of 3 quarters · filed 2020-11-27 | -$76.96M derived: sum of 4 quarters · filed 2020-11-27 |
| 2018-09-30 | -$19.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-27 | -$37.39M derived: sum of 2 quarters · filed 2020-11-27 | -$54.25M derived: sum of 3 quarters · filed 2020-11-27 | -$71.18M 10-K · filed 2020-11-27 |
| 2018-06-30 | -$17.61M 10-Q · filed 2019-08-09 | -$34.47M derived: sum of 2 quarters · filed 2019-08-09 | -$51.40M 10-Q · filed 2019-08-09 | |
| 2018-03-31 | -$16.86M 10-Q · filed 2019-05-02 | -$33.79M 10-Q · filed 2019-05-02 | ||
| 2017-12-31 | -$16.93M 10-Q · filed 2019-02-11 | |||
| 2017-09-30 | -$59.29M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |